Page 8 - Consilient Health News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics January 28, 2021 08:05 ET | Source: Aeterna Zentaris Inc Aeterna Zentaris Inc Montreal CANADA - Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis optica spectrum disorder - Initial step in growth strategy to build-out pipeline of assets - Aeterna Zentaris to develop potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need and significant market opportunity CHARLESTON, S.C., Jan. 28, 2021 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical compa

United statesUnited kingdomJenene thomasAeterna zentaris gmbJoerg wischhusenKlaus pauliniValentin bruttelAeterna zentarisMegapharm ltdEuropean commissionExchange commissionWuerzburg the universityAeterna zentaris incPalestinian authorityEuropean unionConsilient health ltd